Nigel has been in the regulated financial services industry for nearly a decade, has previously owned a financial brokerage and has written many times for sites relating to personal finance and trading.
Merck (NYSE: MRK) stock price continues its slow gains moving into Thursday market open, entering into a new agreement with biopharmaceutical company Acceleron Pharma Inc, (NASDAQ: XLRN).
Extending its gradual gains, Merck has today announced a new venture involving the acquisition of Acceleron through a subsidiary for $180 per share – at an aggregate cost of $11.5 billion.
Acceleron’s noticeable progress with their work in cell growth certainly hasn’t slipped under the radar. Focusing on life-threatening cardiovascular disorders such as pulmonary arterial hypertension (PAH), its key therapeutic candidate ‘Sotatercept’ is currently in Phase 3 of clinical trials.
Rob Davis, CEO and President of Merck announced; “Acceleron’s innovative research has yielded an exciting late-stage candidate that complements and strengthens our growing cardiovascular portfolio and pipeline and holds the potential to build upon Merck’s proud legacy in cardiovascular disease”
With Habib Dable, CEO and President of Acceleon adding:
“We believe Merck is well-positioned to apply its industry-leading clinical and commercial capabilities to harness the potential of sotatercept as we join together to help make an impact on cardiopulmonary disease for the benefit of patients.”
While writing, Merck price has remained relatively steady in its gains, currently trading around $76.38 at a gain of roughly 1.84%. The acquisition and total share transfer is set to finalise in the fourth quarter of 2021.
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .